Amber Implants Appoints Vincent Gardès to Lead VCFix® Spinal System Launch

Leadership Transition at Amber Implants

Amber Implants, a pioneering company in medical technology focused on next-generation spinal injury solutions, has officially announced the appointment of Vincent Gardès as its new Chief Executive Officer. This significant leadership transition comes as the company prepares for the U.S. market launch of its VCFix® Spinal System, scheduled for 2026 following recent clearance from the FDA.

Vincent Gardès, who previously served as the Chairman of the Board for four years, steps into the CEO role during a transformative phase for Amber Implants that marks a shift from development to commercialization. This apppointment underscores the company’s commitment to advancing spinal fracture care through innovative technology. He will work closely with Dr. Banafsheh Sajadi, the Co-Founder and now Chief Operating Officer.

With an impressive background spanning three decades in the MedTech sector, Vincent brings a wealth of experience in commercial strategy, market expansion, and value creation. His previous successes include his tenure as CEO of Vexim, where he turned a fledgling spinal implant firm into a successful international entity, contributing to its IPO and subsequent acquisition by Stryker in 2017. His extensive experience in various senior leadership and advisory roles reinforces Amber's mission to revolutionize spinal treatment methods.

In his new role, Gardès expressed enthusiasm about the VCFix® technology, emphasizing its potential to reshape spinal fracture care. He stated, "Amber's VCFix® technology embodies innovation in spinal treatment, and the upcoming U.S. market entry is crucial. I am excited to collaborate with our team to deliver this transformative solution to healthcare professionals and patients across the globe."

Dr. Sajadi echoed this sentiment, citing Gardès' extensive experience as perfectly aligned with Amber's vision and the company's next steps in growth. They are both focused on not only advancing spinal fracture treatments but also expanding their global influence.

Amber Implants is strategically positioned to enhance its operations by preparing for expansive U.S. commercialization. The company aims to forge worthwhile strategic partnerships while scaling its operations to meet increasing global demand for its VCFix® Spinal System. The recent FDA clearance culminated in a key milestone for commercialization, allowing it to efficiently enter various global markets where such approvals are acknowledged.

This transition emphasizes Amber Implants' commitment to improving patient outcomes through innovative spinal care solutions. The company plans to leverage its current strong portfolio of patents and the ongoing development of its Spinoza Fixation System pipeline. Industry experts anticipate that Amber is poised to capture a substantial portion of the $2 billion plus global vertebral compression fracture market by 2029.

Amber Implants, established in 2018 and operating in both the Netherlands and the U.S., is dedicated to developing groundbreaking spinal implants aimed at enhancing healing processes and spinal stability. The VCFix® Spinal System, its flagship offering, is designed to provide a simplified, more effective, and safe method for managing a variety of spinal fractures. This dedication to innovation and improvement of patient outcomes lays the groundwork for the company's next phase of growth as they prepare to bring their pioneering solutions to the market.

This new chapter for Amber Implants, guided by Vincent Gardès, positions the company to take a significant step forward in transforming spinal fracture management, a critical area in medical technology. The anticipation for the U.S. launch adds to the excitement surrounding the potential impacts of their innovative solutions.